Tasly Pharmaceutical Group Co Ltd (Tasly) develops, manufactures, and distributes chemical medicine, modern Chinese medicine, biological medicine, healthcare products, and functional food. The company focuses on therapeutic areas that include cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological. The company’s cardiovascular and cerebrovascular products include Compound Danshen Dripping Pills, Xingnaojing Zhusheye, Qishen Yiqi Dripping Pills, Zhusheyong Yiqifumai, Lisinopril and Hydrochlorothiazide Tablets, Bezafibrate Tablets, Diltiazem Hydrochloride for Injection, Shaoma Zhijing Keli, Zhusheyong Danshen Duofensuan, Dexzopiclone Tablets, Angong Niuhuang Wan, Recombinant Human Prourokinase, and Lisinopril Capsules. Its hepato-biliary-pancreatic products include Silibinin Capsules. Tasly's respiratory system products include Chuanxinlian Neizhi Dripping Pills. The company’s diabetes products include Xiaokeqing Keli and Metformin Hydrochloride Tablets. Its tumor immunity products include Gefitinib Tablets, Temozolomide Capsules, Flutamide Tablets, and Xihuang Wan. Tasly's gastrointestinal disease products include Jinghua Weikang Jiaowan. The company’s gynecological products include Minodronic Acid Tablets and Kunling Wan. Its rheumatism products include Tianma Wan. The company’s soothe the nerves products include Jinkui Shenqi Wan. Tasly's pruritus products include Fexofenadine Hydrochloride Capsules. The company’s andrological products include Tadalafil Tablets. Tasly also offers over-the-counter drugs, including Yangxue Qingnao Wan, Yangxue Qingnao Keli, Chuanxinlian Neizhi Dripping Pills, Tankejing Dripping Pills, and Chaihu Dripping Pills.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Tasly engages in research and development initiatives, focusing on innovation-driven development to establish itself as a leading enterprise in the Chinese pharmaceutical market. The company concentrates on three core areas: cardiovascular and metabolic diseases, neurology/psychiatry, and digestive diseases. It is committed to developing innovative traditional Chinese medicines and advanced therapeutic drugs. Tasly has structured an open innovation system based on a "disease tree" and a "product tree" model to enhance R&D capabilities and efficiency. The company has expanded its study of Dongpuyouke to include stroke patients within 24 hours of onset, with promising results in reducing intracranial hemorrhage. In 2025, the company has 31 innovative drugs under development, some of which are in the NDA/Pre-NDA stage. Tasly has established several R&D units, including the CMC Development & Research Platform, Pre-clinical Research Platform, and Clinical Research Platform. The CMC Development & Research Platform focuses on developing high-yield cell line screening and optimizing production processes in line with GMP standards. The Pre-clinical Research Platform collaborates with global laboratories and GLP centers to promote pharmacological and toxicological evaluations. The Clinical Research Platform provides international medical evaluation and clinical operation, along with pharmacovigilance and quality compliance systems. The company holds 1,094 patents, including 968 invention patents. Its main product, Compound Danshen Dripping Pills, holds 161 patents. In 2025, the company and its major subsidiaries had 68 patent applications and 42 granted patents. There were 49 new applications and 36 new authorizations for invention patents in China. The company has 31 innovative drugs under development In FY2025, the company spent CNY685.6 million on its R&D activities, which as a percentage of revenue stood at 8.3%, and declined 17.4% YoY.